Albany, NY, United States
Albany, NY, United States

Time filter

Source Type

News Article | February 23, 2017
Site: co.newswire.com

Synergy Pharmacy Services proudly announces its achievement of PCAB accreditation, a service of Accreditation Commission of Health Care (ACHC), thus joining an elite group of pharmacies nationwide with this distinction. The accreditation demonstrates that Synergy Pharmacy Services meets the highest quality and safety standards in its profession. To earn PCAB Accreditation, Synergy Pharmacy Services had to complete an extensive application, document its written policies and provide an analysis of its quality procedures that was reviewed by the Pharmacy Compounding Accreditation Board and some of the leading figures in the field of compounding. Next, the pharmacy opened its doors for an extensive on-site inspection led by compounding experts. Only when these stringent evaluations were completed did the Pharmacy Compounding Accreditation Board officially grant Synergy Pharmacy Services the PCAB Seal of Accreditation and the right to use the designation “PCAB Accredited™ compounding pharmacy.” “We are honored by this accreditation. It confirms our dedication to protecting our patients by practicing safe, high-quality personalized solutions that address patient’s medical needs,” said Michael Palso, Synergy Pharmacy Services COO. “We believe this will only further strengthen the bonds of trust between our pharmacy, the patients, and the healthcare providers who rely on us for these specialized medications.” Compounding medications is an integral part of the practice of pharmacy and the demand for these customized medications increases every year. Compounded medications are prescriptions that are written by physicians, veterinarians, and other legally authorized prescribers and prepared for an individual patient by a specially trained pharmacist. The Pharmacy Compounding Accreditation Board is a not-for-profit corporation formed by eight national pharmacy organizations that recognized the need for a national standards organization for compounding pharmacy. Together, these leading organizations developed the policies and standards for the practice of compounding pharmacy, as well as the PCAB Accreditation criteria and processes. For more information on PCAB Accreditation, visit the PCAB Web site at www.pcab.org. Established in 2010, Synergy Pharmacy Services is an award-winning specialty pharmacy. With a focus on pain management, Synergy Pharmacy Services provides compounding, specialty drugs, and retail services to patients nationwide. In addition to the newly appointed PCAB accreditation, Synergy is a proud member of the International Academy of Compounding Pharmacists (IACP), National Association of Boards of Pharmacy, American College of Apothecaries (ACA), and Florida Pharmacy Association (FPA). For more information about Synergy Pharmacy Services, Inc, please visit www.synergyrx.com.


BETHLEHEM, PA--(Marketwired - Feb 14, 2017) -  B. Braun Medical Inc., a leader in customized parenteral nutrition, will present its new parenteral nutrition program -- PN360 -- designed to improve neonatal, pediatric and adult patient outcomes -- at this year's American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Nutrition Week. "Our PN360 program unlocks a holistic, therapeutic approach to parenteral nutrition through our comprehensive offering of products, education, training and consultative services," said Rick Williamson, Vice President of Pharmaceutical Marketing at B. Braun. "PN360 is a team approach to help meet any facility's parenteral nutrition admixing needs," he said. "The program is more than individual in-house compounding, parenteral nutrition solutions and outsourced compounded products or services. It's an earnest collaboration with pharmacists, physicians, nurses and dietitians to tailor nutritional therapy for their most critical patients, as well as help reduce medical errors, infections and re-admissions." From Feb. 18-20 in the Marriott Orlando World Center in Orlando, Fla., B. Braun representatives at booth #201 also will showcase the company's new macro and micro APEX® compounding system for facilities that need in-house compounding capabilities. Through its browser-based TPN Manager software, health care providers can enter parenteral nutrition orders at the patient's bedside using an iPad or tablet with access to Trissel's Ca/P Safety Check Software™. These orders are EMR integrated and electronically transmitted to the APEX compounder, thereby helping to reduce manual programming errors, eliminate transcription errors, and expedite patient care. B. Braun also offers a wide selection of amino acid formulations, standard solutions, and related additives -- in containers that are not made with natural rubber latex, PVC or DEHP -- to help clinicians provide safe, appropriate nutritional support for patients' individualized needs. B. Braun was the first medical device manufacturer to remove harmful PVC and DEHP from many of its products. To learn more about B. Braun's commitment to protecting people and the environment while improving patient outcomes and reducing health care costs visit www.bbrauncares.com. Another integral part of PN360 is Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company -- the nation's largest network of outsourcing admixture pharmacies and a leader in customized parenteral nutrition. CAPS representatives will be at the booth to discuss the company's customized parenteral nutrition compounding services, including local, same-day delivery with safe, easy online ordering and a pharmacist to double-check on each order. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the health care industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


News Article | November 30, 2016
Site: www.marketwired.com

IRVINE, CA--(Marketwired - Nov 30, 2016) - Central Admixture Pharmacy Services, Inc. (CAPS®) will present its new quality assurance program requiring 100 percent release testing of all of its compounded drugs and other products at this year's American Society of Health-System Pharmacists (ASHP) 51st Midyear Clinical Meeting. From Dec. 5-7 in the Mandalay Bay Convention Center in Las Vegas, CAPS representatives will be at booth #2413 to discuss the company's Test, Hold and Release (THR(SM)) program, which is designed to ensure that every compounded drug batch from CAPS' 503B outsourcing facilities meets the new standards for cGMP release testing for sterility, potency, and endotoxin testing prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind. "Our existing high quality standards are strengthened with THR implementation, which requires 100 percent release testing on all of our products," said Mike Koch, Senior Vice President, CAPS Professional Services. "When it comes to patient safety and the reputation of our customers, we believe that THR for every batch is the only way to assure the level of quality that's demanded by pharmacists and clinicians to enhance patient outcomes." CAPS was among the first outsourcing admixture pharmacies in the nation to adopt release testing. "CAPS is at the forefront of helping hospitals and surgery centers navigate through the new compounding regulatory environment," Koch said. "Our goal is to provide our customers with programs such as THR and consultative services to help them focus on improving patient care." A market leader in customized Parenteral Nutrition (PN) delivery and provider of quality sterile compounding services for the past 25 years, CAPS also will feature CAPS Consulting(SM), a new service designed to help hospital pharmacists and pharmacies remain compliant in light of new regulations as a result of the Drug Quality & Security Act. CAPS Consulting offers comprehensive evaluations of pharmacies, assesses compliance readiness, and provides recommendations and training. About CAPS® CAPS is the nation's largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including PN and chemotherapy. To learn more, visit www.capspharmacy.com. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


News Article | February 16, 2017
Site: www.businesswire.com

CREVE COEUR, Miss.--(BUSINESS WIRE)--Focus Script LLC, a leading independent specialized pharmacy claims management company and Arete Pharmacy Network, LLC, a national quality-focused Pharmacy Services Administrative Organization (PSAO), announced an exclusive partnership today. The partnership extends FocusScript’s compounding pharmacy accreditation, credentialing, and ongoing oversight to independent compounding pharmacies that are member pharmacies of Arete Pharmacy Network. The agreement means that the two companies will collaborate to ensure that Arete Pharmacy Network’s current and prospective compounding member pharmacies meet accreditation and credentialing standards incorporating compliance, quality, and performance standards necessary to compete on excellence in today’s managed care environment. Ensuring a pool of quality compounding pharmacies allows Pharmacy Benefit Managers (PBMs) and payors to grant contract access to the compounding pharmacies with confidence. Under the terms of the agreement, FocusScript will certify that pharmacies are accredited and credentialed through the industry leading UCAP program, which is administered through FocusScript’s exclusive partnership with the National Association of Boards of Pharmacy (NABP). Additionally, FocusScript will manage and process claims through its proprietary pre-processing system to deliver optimal pricing, broad analytics, and real-time oversight of Fraud, Waste and Abuse. Rob McMahan, CEO of Arete Pharmacy Network said, “The relationship between Arete Pharmacy Network and FocusScript will have immense benefits for both our member pharmacies and the payors we work with. Our collaboration with FocusScript—an expert in the compounding pharmacy field—reinforces our commitment to building a quality network by providing an additional avenue to serve compounding pharmacies.” Cynthia A. Meiners, President and CEO, Focus Script, LLC, stated, “FocusScript is dedicated to aligning the right people, shared values and technology needed to organize and oversee the delivery of quality standards, rational pricing and reasonable business practices to complex pharmacy markets. FocusScript provides the confidence to clients and providers that they can compete in these markets by offering optimum quality standards, pricing, and intelligent editing utilizing best practices with diligent oversight. We are excited to partner with the Arete Pharmacy Network in its commitment to these shared values.” Arete Pharmacy Network serves independent community pharmacies through a portfolio of expanded tools and services designed to help pharmacies deliver quality care to their communities. With a core focus on managed care contracting and service excellence, Arete Pharmacy Network supports the effective management of the financial, quality, and operational aspects of pharmacy business. For more information, visit www.areterx.com. Founded in 2014, the Company provides access to a network of certified pharmacies that provide specialized and compounded medications. Through an exclusive partnership with the National Association of Boards of Pharmacy (“NABP”), FocusScript’s network of compounding pharmacies is certified through the United Credentialing and Accreditation Program (“UCAP”). Using NABP’s Verified Pharmacy Program (“VPP”) as its foundation, the UCAP program includes a rigorous review of business and quality practices, attestation to a code of conduct, and compounding specific requirements. FocusScript is independent and unbiased, enabling us to work with all stakeholders and suppliers and to compete solely on excellence. For more information, visit www.focusscript.com.


News Article | November 22, 2016
Site: www.newsmaker.com.au

This report studies sales (consumption) of Compounding Pharmacy in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering Market Segment by Countries, this report splits Europe into several key Countries, with sales (consumption), revenue, market share and growth rate of Compounding Pharmacy in these countries, from 2011 to 2021 (forecast), like Germany France UK Russia Italy Spain Benelux Split by product type, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by application, this report focuses on sales, market share and growth rate of Compounding Pharmacy in each application, can be divided into View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/europe-compounding-pharmacy-market-report-2016 Europe Compounding Pharmacy Market Report 2016 1 Compounding Pharmacy Overview 1.1 Product Overview and Scope of Compounding Pharmacy 1.2 Classification of Compounding Pharmacy 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Compounding Pharmacy 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Compounding Pharmacy Market by Countries 1.4.1 Germany Status and Prospect (2011-2021) 1.4.2 France Status and Prospect (2011-2021) 1.4.3 UK Status and Prospect (2011-2021) 1.4.4 Russia Status and Prospect (2011-2021) 1.4.5 Italy Status and Prospect (2011-2021) 1.4.6 Spain Status and Prospect (2011-2021) 1.4.7 Benelux Status and Prospect (2011-2021) 1.5 Europe Market Size (Value and Volume) of Compounding Pharmacy (2011-2021) 1.5.1 Europe Compounding Pharmacy Sales and Growth Rate (2011-2021) 1.5.2 Europe Compounding Pharmacy Revenue and Growth Rate (2011-2021) 10 Europe Compounding Pharmacy Manufacturers Analysis 10.1 Central Admixture Pharmacy Services 10.1.1 Company Basic Information, Manufacturing Base and Competitors 10.1.2 Compounding Pharmacy Product Type, Application and Specification 10.1.2.1 Type I 10.1.2.2 Type II 10.1.3 Central Admixture Pharmacy Services Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 10.1.4 Main Business/Business Overview 10.2 Fagron 10.2.1 Company Basic Information, Manufacturing Base and Competitors 10.2.2 Compounding Pharmacy Product Type, Application and Specification 10.2.2.1 Type I 10.2.2.2 Type II 10.2.3 Fagron Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 10.2.4 Main Business/Business Overview 10.3 Fresenius Kabi AG 10.3.1 Company Basic Information, Manufacturing Base and Competitors 10.3.2 Compounding Pharmacy Product Type, Application and Specification 10.3.2.1 Type I 10.3.2.2 Type II 10.3.3 Fresenius Kabi AG Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 10.3.4 Main Business/Business Overview 10.4 PharMEDium Services, LLC 10.4.1 Company Basic Information, Manufacturing Base and Competitors 10.4.2 Compounding Pharmacy Product Type, Application and Specification 10.4.2.1 Type I 10.4.2.2 Type II 10.4.3 PharMEDium Services, LLC Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 10.4.4 Main Business/Business Overview 10.5 Institutional Pharmacy Solutions 10.5.1 Company Basic Information, Manufacturing Base and Competitors 10.5.2 Compounding Pharmacy Product Type, Application and Specification 10.5.2.1 Type I 10.5.2.2 Type II 10.5.3 Institutional Pharmacy Solutions Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 10.5.4 Main Business/Business Overview 10.6 Cantrell Drug Company 10.6.1 Company Basic Information, Manufacturing Base and Competitors 10.6.2 Compounding Pharmacy Product Type, Application and Specification 10.6.2.1 Type I 10.6.2.2 Type II 10.6.3 Cantrell Drug Company Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 10.6.4 Main Business/Business Overview Global QYResearch is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


LONDON, UK / ACCESSWIRE / March 1, 2017 / Active Wall St. announces its post-earnings coverage on CVS Health Corp. (NYSE: CVS). The Company released its financial results for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17) on February 09, 2017. The Drugstore chain and pharmacy benefits manager's earnings outperformed market expectations. Register with us now for your free membership at: One of CVS Health's competitors within the Health Care Plans space, Magellan Health, Inc. (NASDAQ: MGLN), reported its earnings for Q4 ended on December 31, 2016, on Friday, February 24, 2017. AWS will be initiating a research report on Magellan Health in the coming days. Today, AWS is promoting its earnings coverage on CVS; touching on MGLN. Get our free coverage by signing up to: CVS announced that net revenues for the three months ended December 31, 2016, increased 11.7% to $46.0 billion, up from $41.1 billion in Q4 2015. The Company's revenue numbers came in below market estimates of $46.51 billion. For the year ended December 31, 2016, CVS' net revenues increased 15.8% to $177.5 billion compared to $153.3 billion for FY15. CVS' net income for Q4 2016 was $1.71 billion, or $1.59 per share, compared to net income of $1.50 billion, or $1.34 per share, during Q4 2015. The Company benefited from a lower effective income tax rate in the reported quarter of 38.0% versus 38.9% in the prior year's same period. CVS' adjusted earnings per share for Q4 2016 was $1.71 compared to $1.53 for Q4 2015, and surpassed analysts' consensus of $1.67 per share. The Company's GAAP diluted EPS for year ended December 31, 2016 was $4.91 compared to $4.62 in the prior year. Net income for the year ended December 31, 2016, was $5.3 billion, an increase of $80 million, or 1.5%. CVS generated approximately $1.5 billion of free cash during the quarter and $8.1 billion for the full year 2016, which was above the high-end of its guidance range. In FY16, CVS returned $6.3 billion to shareholders through dividends and share repurchases. During Q4 2016, the Company repurchased 6.1 million shares for $461 million, or $75.20 per share. In FY16, CVS repurchased 48 million shares for $4.5 billion, or $96.78 per share. CVS's revenues in the Pharmacy Services segment increased 17.9% to $31.3 billion in Q4 2016, primarily driven by growth in pharmacy network and specialty pharmacy claims. Pharmacy network claims processed during the reported period, increased 23.9% to 294.3 million, compared to 237.4 million in the prior year. The increase in pharmacy network claim volume was primarily due to an increase in net new business. CVS' Mail choice claims processed during Q4 2016, increased 4.7% to 23.2 million compared to 22.2 million in the prior year. CVS' revenues in the Retail/LTC segment increased 4.7% to $20.8 billion in Q4 2016, largely driven by the addition of the pharmacies of Target Corporation, which were acquired in December 2015. Pharmacy same store prescription volumes rose 2.0% on a 30-day equivalent basis. Same store sales decreased 0.7% versus the prior year, with pharmacy same store sales up 0.2% and front store same store sales down 2.9%. Front store same store sales were negatively impacted by softer customer traffic and efforts to rationalize promotional strategies, partially offset by an increase in basket size. Pharmacy same store sales were negatively impacted for Q4 2016 by approximately 380 basis points due to recent generic introductions. CVS reported that for Q4 2016, the generic dispensing rate increased approximately 170 basis points to 85.4% in its Pharmacy Services segment and increased approximately 120 basis points to 85.2% in the Company's Retail/LTC segment compared to the prior year. For Q4 2016, CVS' consolidated operating profit increased $266 million. Operating profit for the reported quarter increased $242 million in the Pharmacy Services segment and decreased $53 million in the Retail/LTC segment. The Pharmacy Services segment operating profit included the favorable impact of a reversal of an accrual of $88 million in connection with a legal settlement. Corporate segment operating expenses decreased $92 million from the prior year primarily due to the $90 million legal charge in the prior year associated with a disputed 1999 legal settlement. For FY16, CVS' consolidated operating profit increased $884 million. Operating profit for the year had increased by $683 million in the Pharmacy Services segment and $151 million in the Retail/LTC segment. During Q4 2016, CVS opened 40 new retail stores and closed 25 retail stores. In addition, the Company relocated 16 retail stores. As of December 31, 2016, the Company operated 9,709 retail stores, including pharmacies in Target stores, in 49 states, the District of Columbia, Puerto Rico and Brazil. CVS intends to close approximately 70 retail stores during 2017 and expects to take a charge of approximately $225 million associated with the remaining lease obligations of such stores. The vast majority of the store closures are expected to occur in Q1 2017. In connection with such anticipated store closures, the Company recorded a $34 million asset impairment charge in Q4 2016. CVS expects to deliver GAAP diluted EPS of $5.02 to $5.18 and adjusted EPS of $5.77 to $5.93 for FY17. The Company expects to deliver GAAP diluted EPS of $0.82 to $0.88 and adjusted EPS of $1.07 to $1.13 in Q1 2017. The Company also confirmed its FY17 cash flow from operations guidance of $7.7 billion to $8.6 billion and free cash flow guidance of $6.0 billion to $6.4 billion. At the close of trading session on Tuesday, February 28, 2017, CVS Health's stock price slipped 1.02% to end the day at $80.58. A total volume of 7.27 million shares were exchanged during the session. The Company's share price has gained 9.46% in the past three months and 2.73% on YTD basis. The stock is trading at a PE ratio of 16.35 and has a dividend yield of 2.48%. Additionally, the stock currently has a market cap of $85.74 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / March 1, 2017 / Active Wall St. announces its post-earnings coverage on CVS Health Corp. (NYSE: CVS). The Company released its financial results for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17) on February 09, 2017. The Drugstore chain and pharmacy benefits manager's earnings outperformed market expectations. Register with us now for your free membership at: One of CVS Health's competitors within the Health Care Plans space, Magellan Health, Inc. (NASDAQ: MGLN), reported its earnings for Q4 ended on December 31, 2016, on Friday, February 24, 2017. AWS will be initiating a research report on Magellan Health in the coming days. Today, AWS is promoting its earnings coverage on CVS; touching on MGLN. Get our free coverage by signing up to: CVS announced that net revenues for the three months ended December 31, 2016, increased 11.7% to $46.0 billion, up from $41.1 billion in Q4 2015. The Company's revenue numbers came in below market estimates of $46.51 billion. For the year ended December 31, 2016, CVS' net revenues increased 15.8% to $177.5 billion compared to $153.3 billion for FY15. CVS' net income for Q4 2016 was $1.71 billion, or $1.59 per share, compared to net income of $1.50 billion, or $1.34 per share, during Q4 2015. The Company benefited from a lower effective income tax rate in the reported quarter of 38.0% versus 38.9% in the prior year's same period. CVS' adjusted earnings per share for Q4 2016 was $1.71 compared to $1.53 for Q4 2015, and surpassed analysts' consensus of $1.67 per share. The Company's GAAP diluted EPS for year ended December 31, 2016 was $4.91 compared to $4.62 in the prior year. Net income for the year ended December 31, 2016, was $5.3 billion, an increase of $80 million, or 1.5%. CVS generated approximately $1.5 billion of free cash during the quarter and $8.1 billion for the full year 2016, which was above the high-end of its guidance range. In FY16, CVS returned $6.3 billion to shareholders through dividends and share repurchases. During Q4 2016, the Company repurchased 6.1 million shares for $461 million, or $75.20 per share. In FY16, CVS repurchased 48 million shares for $4.5 billion, or $96.78 per share. CVS's revenues in the Pharmacy Services segment increased 17.9% to $31.3 billion in Q4 2016, primarily driven by growth in pharmacy network and specialty pharmacy claims. Pharmacy network claims processed during the reported period, increased 23.9% to 294.3 million, compared to 237.4 million in the prior year. The increase in pharmacy network claim volume was primarily due to an increase in net new business. CVS' Mail choice claims processed during Q4 2016, increased 4.7% to 23.2 million compared to 22.2 million in the prior year. CVS' revenues in the Retail/LTC segment increased 4.7% to $20.8 billion in Q4 2016, largely driven by the addition of the pharmacies of Target Corporation, which were acquired in December 2015. Pharmacy same store prescription volumes rose 2.0% on a 30-day equivalent basis. Same store sales decreased 0.7% versus the prior year, with pharmacy same store sales up 0.2% and front store same store sales down 2.9%. Front store same store sales were negatively impacted by softer customer traffic and efforts to rationalize promotional strategies, partially offset by an increase in basket size. Pharmacy same store sales were negatively impacted for Q4 2016 by approximately 380 basis points due to recent generic introductions. CVS reported that for Q4 2016, the generic dispensing rate increased approximately 170 basis points to 85.4% in its Pharmacy Services segment and increased approximately 120 basis points to 85.2% in the Company's Retail/LTC segment compared to the prior year. For Q4 2016, CVS' consolidated operating profit increased $266 million. Operating profit for the reported quarter increased $242 million in the Pharmacy Services segment and decreased $53 million in the Retail/LTC segment. The Pharmacy Services segment operating profit included the favorable impact of a reversal of an accrual of $88 million in connection with a legal settlement. Corporate segment operating expenses decreased $92 million from the prior year primarily due to the $90 million legal charge in the prior year associated with a disputed 1999 legal settlement. For FY16, CVS' consolidated operating profit increased $884 million. Operating profit for the year had increased by $683 million in the Pharmacy Services segment and $151 million in the Retail/LTC segment. During Q4 2016, CVS opened 40 new retail stores and closed 25 retail stores. In addition, the Company relocated 16 retail stores. As of December 31, 2016, the Company operated 9,709 retail stores, including pharmacies in Target stores, in 49 states, the District of Columbia, Puerto Rico and Brazil. CVS intends to close approximately 70 retail stores during 2017 and expects to take a charge of approximately $225 million associated with the remaining lease obligations of such stores. The vast majority of the store closures are expected to occur in Q1 2017. In connection with such anticipated store closures, the Company recorded a $34 million asset impairment charge in Q4 2016. CVS expects to deliver GAAP diluted EPS of $5.02 to $5.18 and adjusted EPS of $5.77 to $5.93 for FY17. The Company expects to deliver GAAP diluted EPS of $0.82 to $0.88 and adjusted EPS of $1.07 to $1.13 in Q1 2017. The Company also confirmed its FY17 cash flow from operations guidance of $7.7 billion to $8.6 billion and free cash flow guidance of $6.0 billion to $6.4 billion. At the close of trading session on Tuesday, February 28, 2017, CVS Health's stock price slipped 1.02% to end the day at $80.58. A total volume of 7.27 million shares were exchanged during the session. The Company's share price has gained 9.46% in the past three months and 2.73% on YTD basis. The stock is trading at a PE ratio of 16.35 and has a dividend yield of 2.48%. Additionally, the stock currently has a market cap of $85.74 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / March 1, 2017 / Active Wall St. announces its post-earnings coverage on CVS Health Corp. (NYSE: CVS). The Company released its financial results for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17) on February 09, 2017. The Drugstore chain and pharmacy benefits manager's earnings outperformed market expectations. Register with us now for your free membership at: One of CVS Health's competitors within the Health Care Plans space, Magellan Health, Inc. (NASDAQ: MGLN), reported its earnings for Q4 ended on December 31, 2016, on Friday, February 24, 2017. AWS will be initiating a research report on Magellan Health in the coming days. Today, AWS is promoting its earnings coverage on CVS; touching on MGLN. Get our free coverage by signing up to: CVS announced that net revenues for the three months ended December 31, 2016, increased 11.7% to $46.0 billion, up from $41.1 billion in Q4 2015. The Company's revenue numbers came in below market estimates of $46.51 billion. For the year ended December 31, 2016, CVS' net revenues increased 15.8% to $177.5 billion compared to $153.3 billion for FY15. CVS' net income for Q4 2016 was $1.71 billion, or $1.59 per share, compared to net income of $1.50 billion, or $1.34 per share, during Q4 2015. The Company benefited from a lower effective income tax rate in the reported quarter of 38.0% versus 38.9% in the prior year's same period. CVS' adjusted earnings per share for Q4 2016 was $1.71 compared to $1.53 for Q4 2015, and surpassed analysts' consensus of $1.67 per share. The Company's GAAP diluted EPS for year ended December 31, 2016 was $4.91 compared to $4.62 in the prior year. Net income for the year ended December 31, 2016, was $5.3 billion, an increase of $80 million, or 1.5%. CVS generated approximately $1.5 billion of free cash during the quarter and $8.1 billion for the full year 2016, which was above the high-end of its guidance range. In FY16, CVS returned $6.3 billion to shareholders through dividends and share repurchases. During Q4 2016, the Company repurchased 6.1 million shares for $461 million, or $75.20 per share. In FY16, CVS repurchased 48 million shares for $4.5 billion, or $96.78 per share. CVS's revenues in the Pharmacy Services segment increased 17.9% to $31.3 billion in Q4 2016, primarily driven by growth in pharmacy network and specialty pharmacy claims. Pharmacy network claims processed during the reported period, increased 23.9% to 294.3 million, compared to 237.4 million in the prior year. The increase in pharmacy network claim volume was primarily due to an increase in net new business. CVS' Mail choice claims processed during Q4 2016, increased 4.7% to 23.2 million compared to 22.2 million in the prior year. CVS' revenues in the Retail/LTC segment increased 4.7% to $20.8 billion in Q4 2016, largely driven by the addition of the pharmacies of Target Corporation, which were acquired in December 2015. Pharmacy same store prescription volumes rose 2.0% on a 30-day equivalent basis. Same store sales decreased 0.7% versus the prior year, with pharmacy same store sales up 0.2% and front store same store sales down 2.9%. Front store same store sales were negatively impacted by softer customer traffic and efforts to rationalize promotional strategies, partially offset by an increase in basket size. Pharmacy same store sales were negatively impacted for Q4 2016 by approximately 380 basis points due to recent generic introductions. CVS reported that for Q4 2016, the generic dispensing rate increased approximately 170 basis points to 85.4% in its Pharmacy Services segment and increased approximately 120 basis points to 85.2% in the Company's Retail/LTC segment compared to the prior year. For Q4 2016, CVS' consolidated operating profit increased $266 million. Operating profit for the reported quarter increased $242 million in the Pharmacy Services segment and decreased $53 million in the Retail/LTC segment. The Pharmacy Services segment operating profit included the favorable impact of a reversal of an accrual of $88 million in connection with a legal settlement. Corporate segment operating expenses decreased $92 million from the prior year primarily due to the $90 million legal charge in the prior year associated with a disputed 1999 legal settlement. For FY16, CVS' consolidated operating profit increased $884 million. Operating profit for the year had increased by $683 million in the Pharmacy Services segment and $151 million in the Retail/LTC segment. During Q4 2016, CVS opened 40 new retail stores and closed 25 retail stores. In addition, the Company relocated 16 retail stores. As of December 31, 2016, the Company operated 9,709 retail stores, including pharmacies in Target stores, in 49 states, the District of Columbia, Puerto Rico and Brazil. CVS intends to close approximately 70 retail stores during 2017 and expects to take a charge of approximately $225 million associated with the remaining lease obligations of such stores. The vast majority of the store closures are expected to occur in Q1 2017. In connection with such anticipated store closures, the Company recorded a $34 million asset impairment charge in Q4 2016. CVS expects to deliver GAAP diluted EPS of $5.02 to $5.18 and adjusted EPS of $5.77 to $5.93 for FY17. The Company expects to deliver GAAP diluted EPS of $0.82 to $0.88 and adjusted EPS of $1.07 to $1.13 in Q1 2017. The Company also confirmed its FY17 cash flow from operations guidance of $7.7 billion to $8.6 billion and free cash flow guidance of $6.0 billion to $6.4 billion. At the close of trading session on Tuesday, February 28, 2017, CVS Health's stock price slipped 1.02% to end the day at $80.58. A total volume of 7.27 million shares were exchanged during the session. The Company's share price has gained 9.46% in the past three months and 2.73% on YTD basis. The stock is trading at a PE ratio of 16.35 and has a dividend yield of 2.48%. Additionally, the stock currently has a market cap of $85.74 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | November 15, 2016
Site: www.newsmaker.com.au

This report studies sales (consumption) of Compounding Pharmacy in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Compounding Pharmacy in each application, can be divided into Application 1 Application 2 Application 3 View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/united-states-compounding-pharmacy-market-report-2016 United States Compounding Pharmacy Market Report 2016 1 Compounding Pharmacy Overview 1.1 Product Overview and Scope of Compounding Pharmacy 1.2 Classification of Compounding Pharmacy 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Compounding Pharmacy 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 United States Market Size Sales (Value) and Revenue (Volume) of Compounding Pharmacy (2011-2021) 1.4.1 United States Compounding Pharmacy Sales and Growth Rate (2011-2021) 1.4.2 United States Compounding Pharmacy Revenue and Growth Rate (2011-2021) 5 United States Compounding Pharmacy Manufacturers Profiles/Analysis 5.1 Central Admixture Pharmacy Services 5.1.1 Company Basic Information, Manufacturing Base and Competitors 5.1.2 Compounding Pharmacy Product Type, Application and Specification 5.1.2.1 Type I 5.1.2.2 Type II 5.1.3 Central Admixture Pharmacy Services Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 5.1.4 Main Business/Business Overview 5.2 Fagron 5.2.2 Compounding Pharmacy Product Type, Application and Specification 5.2.2.1 Type I 5.2.2.2 Type II 5.2.3 Fagron Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 5.2.4 Main Business/Business Overview 5.3 Fresenius Kabi AG 5.3.2 Compounding Pharmacy Product Type, Application and Specification 5.3.2.1 Type I 5.3.2.2 Type II 5.3.3 Fresenius Kabi AG Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 5.3.4 Main Business/Business Overview 5.4 PharMEDium Services, LLC 5.4.2 Compounding Pharmacy Product Type, Application and Specification 5.4.2.1 Type I 5.4.2.2 Type II 5.4.3 PharMEDium Services, LLC Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 5.4.4 Main Business/Business Overview 5.5 Institutional Pharmacy Solutions 5.5.2 Compounding Pharmacy Product Type, Application and Specification 5.5.2.1 Type I 5.5.2.2 Type II 5.5.3 Institutional Pharmacy Solutions Compounding Pharmacy Sales, Revenue, Price and Gross Margin (2011-2016) 5.5.4 Main Business/Business Overview Global QYResearch is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


News Article | February 24, 2017
Site: www.prnewswire.com

PALM HARBOR, Fla., Feb. 23, 2017 /PRNewswire/ -- Synergy Pharmacy Services proudly announces its achievement of PCAB accreditation, a service of Accreditation Commission of Health Care (ACHC), thus joining an elite group of pharmacies nationwide with this distinction. The accreditation...


News Article | February 15, 2017
Site: www.prweb.com

The Excelera network consists of point-of-care specialty pharmacies owned by health systems and academic medical centers. The network provides members nationally scaled infrastructure and support to help them develop best practices and gain access to limited-distribution drugs and biologics and restrictive payer agreements so members can provide continuity of care for their patients with complex and chronic conditions requiring specialty drugs and biologics. The network also serves as a national platform for collaboration to optimize outpatient specialty drug therapy for population health. “Partnering with Excelera to develop our specialty pharmacy operations is a win for our most complex patients, who will receive comprehensive specialty services more expeditiously than if we were to go it alone,” said Kyle Townsend, Director of Pharmacy Services Billings Clinic. “Plus, we get the benefit of access and insight from thought leaders across the country who are grappling with the same challenges of providing high-quality care at a reduced cost with the best possible patient outcomes.” “Billings Clinic is a physician-led, integrated multispecialty group practice that exemplifies the highest national standards in hospital care and management,” said Jim Fox, Chief Executive Officer of the Excelera network. “We are pleased to welcome Billings Clinic into our national network and look forward to building an enduring relationship.” Specialty pharmaceuticals are expensive drugs that require special handing and administration and are often used to treat the most ill and clinically complex patients. The Excelera organization will partner with Billings Clinic to develop key specialty pharmacy capabilities including training, operations, data aggregation, reporting for drug manufacturers and payers, revenue cycle management and pharmacy business office. ExceleraRx Corp. supports the Excelera® Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, enabling member organizations to gain access to limited distribution drugs and restricted payer agreements. The Excelera network provides national-scale efficiency and collaboration to improve quality and value of outpatient specialty drug therapy for population health outcomes. Excelera’s mission is to “provide tools, technology and best practices around high-performing specialty pharmacy capabilities to network members, so that they can provide integrated, coordinated care to complex patients at the point-of-care leading to improved health outcomes and decreased healthcare costs.” For a current list of Excelera specialty pharmacy network members, or for more information about becoming a member of the Excelera national specialty pharmacy network, visit excelerarx.com or follow us on LinkedIn. Billings Clinic is Montana’s largest health system serving Montana, Wyoming and the western Dakotas. A not-for-profit organization led by a physician CEO, Billings Clinic is governed by a board of community members, nurses and physicians. At its core, Billings Clinic is a physician-led, integrated multispecialty group practice with a 304-bed hospital and Level II trauma center. Billings Clinic has more than 4,100 employees, including 450 physicians and advanced practitioners offering more than 50 specialties. More information can be found at http://www.billingsclinic.com

Loading Pharmacy Services collaborators
Loading Pharmacy Services collaborators